Literature DB >> 1455912

Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area.

M R Wills1, B K Sil, J X Cao, Y X Yu, A D Barrett.   

Abstract

In China, a live attenuated Japanese encephalitis (JE) vaccine, based on strain SA14-14-2, has been derived from the wild-type strain SA14 as an alternative to the current inactivated vaccines such as Nakayama-NIH and P-3. SA14-14-2 has been characterized using monoclonal antibodies derived in mice, using HAI and neutralization tests, and compared with other Chinese live vaccine clones and 14 wild-type strains of JE virus. Wild-type strain SA14 was found to be a poor immunogen and antigenically distant from all other viruses examined. The vaccine derivatives SA14-5-3 was more immunogenic than its wild-type parent, while SA14-14-2 (derived from SA14-5-3) was more immunogenic than SA14-5-3 and elicited a cross neutralizing antibody response. Our studies indicated that JE virus strain Nakayama elicited as good a neutralizing antibody response in hyperimmunized mice as the SA14-14-2 vaccine clones grown in either primary hamster kidney (PHK) or primary dog kidney (PDK) cells. A single dose of live SA14-14-2 (PHK) also elicited a good antibody response. Antigenic variation between wild-type and vaccine clones of JE virus were detected but were not considered significant in terms of controlling JE virus infections by vaccination.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455912     DOI: 10.1016/0264-410x(92)90051-k

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Comparison of the genome sequences and the phylogenetic analyses of the GP78 and the Vellore P20778 isolates of Japanese encephalitis virus from India.

Authors:  S Vrati
Journal:  J Biosci       Date:  2000-09       Impact factor: 1.826

2.  Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Authors:  T P Monath; I Levenbook; K Soike; Z X Zhang; M Ratterree; K Draper; A D Barrett; R Nichols; R Weltzin; J Arroyo; F Guirakhoo
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.

Authors:  Peter E Nasveld; Andrew Ebringer; Nathan Elmes; Sonya Bennett; Sutee Yoksan; John Aaskov; Karen McCarthy; Niranjan Kanesa-thasan; Claude Meric; Mark Reid
Journal:  Hum Vaccin       Date:  2010-12-01

4.  Development of a vaccine to prevent Japanese encephalitis: a brief review.

Authors:  Viroj Wiwanitkit
Journal:  Int J Gen Med       Date:  2009-12-29

Review 5.  Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.

Authors:  Carlo Amorin Daep; Jorge L Muñoz-Jordán; Eliseo Alberto Eugenin
Journal:  J Neurovirol       Date:  2014-10-07       Impact factor: 2.643

6.  Envelope Protein Mutations L107F and E138K Are Important for Neurovirulence Attenuation for Japanese Encephalitis Virus SA14-14-2 Strain.

Authors:  Jian Yang; Huiqiang Yang; Zhushi Li; Wei Wang; Hua Lin; Lina Liu; Qianzhi Ni; Xinyu Liu; Xianwu Zeng; Yonglin Wu; Yuhua Li
Journal:  Viruses       Date:  2017-01-21       Impact factor: 5.048

7.  Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.

Authors:  Emmanuel Feroldi; Mark Boaz; Sutee Yoksan; Kulkanya Chokephaibulkit; Usa Thisyakorn; Chitsanu Pancharoen; Céline Monfredo; Alain Bouckenooghe
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

8.  Full-Length Genome Sequence of Japanese Encephalitis Virus Strain FC792, Isolated from Guangxi, China.

Authors:  Bingxia Lu; Yibin Qin; Bin Li; Ying He; Qunpeng Duan; Jiaxing Liang; Zhongwei Chen; Qianlian Su; Bingfen Bi; Wu Zhao
Journal:  Genome Announc       Date:  2017-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.